acetylcholinesterase
acetylcholinesterase
Overview
Acetylcholinesterase (AChE; EC 3.1.1.7) is a serine hydrolase enzyme responsible for the rapid hydrolysis of the neurotransmitter acetylcholine (ACh) at cholinergic synapses, terminating synaptic transmission in both the central and peripheral nervous systems. By cleaving acetylcholine into choline and acetate, AChE regulates the duration and intensity of cholinergic signaling, making it indispensable for normal neuromuscular function, autonomic regulation, and cognitive processes including learning and memory. AChE is expressed across diverse tissue types — most prominently in neurons, erythrocytes, and neuromuscular junctions — and its activity in red blood cells and plasma serves as a standard clinical biomarker of neurophysiological health. Inhibition of AChE increases synaptic acetylcholine levels, a mechanism exploited therapeutically in Alzheimer's disease (AD) management via drugs such as donepezil. Conversely, toxic suppression of AChE by organophosphate compounds — including pesticides and chemical warfare agents — underlies cholinergic toxidrome, a potentially fatal syndrome characterized by excessive glandular secretion, bronchospasm, and seizures.
Beyond its canonical synaptic role, AChE participates in non-classical functions including cell adhesion, neurite outgrowth, and responses to cellular stress such as hypoxia and oxidative stress. Closely related to butyrylcholinesterase (BChE), which also hydrolyzes acetylcholine and other esters with broader substrate specificity, AChE remains the primary pharmacological target in Alzheimer's disease research. The co-occurrence of AChE dysregulation with metabolic conditions including diabetes and comorbidities such as oxidative stress has expanded its relevance beyond pure neuropharmacology into integrative biomedical research.
Recent Publications Focus
Below is a summary of the newest research publications targeting acetylcholinesterase (sorted by publication date).
Recent research on acetylcholinesterase has predominantly focused on developing novel inhibitors as therapeutic candidates for Alzheimer's disease and related neurodegenerative conditions. Investigators have employed diverse approaches, including the synthesis of synthetic organic compounds, evaluation of plant-derived natural products, and computational drug discovery methods. A major application has been the development of machine learning-based QSAR models to predict acetylcholinesterase inhibitor activity [42390765], while multiple chemical scaffolds have been rationally designed and synthesized, including coumarin-based derivatives [41691754], thieno[3,2-d]pyrimidine hybrids [41871474], chiral anthranilic diamide derivatives [42050895], benzothiazole-oxadiazole compounds [41797133], and chromeno[4,3-b]quinoline structures [42179001]. Natural products from medicinal plants, including extracts from Salvia heldreichiana [42220228], Epimedium pubigerum [41806791], Bellis annua [42012914], and olive leaves [40960191], have also been evaluated for their acetylcholinesterase inhibitory potential.
A substantial body of recent literature has focused on multi-target-directed ligands that simultaneously inhibit acetylcholinesterase and butyrylcholinesterase, reflecting the observation that both enzymes are dysregulated in advanced Alzheimer's disease stages. Potent dual inhibitors have been developed, including quinazolinone-chalcone hybrids with IC₅₀ values as low as 0.108 µg/mL for butyrylcholinesterase [42149153], hydrazide-hydrazone indole congeners targeting acetylcholinesterase, BACE1, and MAO-B [41865568], and thieno[3,2-d]pyrimidine-phenolic Mannich base derivatives exhibiting Ki values in the low nanomolar range for both cholinesterases [41871474]. Multi-target compounds have also been designed to address broader pathogenic mechanisms in Alzheimer's disease, including inhibitors that simultaneously target acetylcholinesterase along with glycogen synthase kinase-3β [41691754], oxidative stress pathways [42154340], and neuroinflammatory mediators [41871474]. Notably, trans-anethole demonstrated neuroprotective effects by inhibiting acetylcholinesterase activity while simultaneously suppressing oxidative stress markers and NLRP3 inflammasome signaling in aluminum-induced neurodegeneration models [42154340].
Beyond Alzheimer's disease, acetylcholinesterase has emerged as a therapeutic target and diagnostic biomarker in diverse clinical contexts. sodium glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin and dapagliflozin, were identified through molecular docking as possessing acetylcholinesterase-inhibitory activity and demonstrated cognitive enhancement in type 2 diabetes-induced cognitive impairment models [41819428], while canagliflozin, a dual SGLT2/acetylcholinesterase inhibitor, improved hippocampal dendrite morphology in Alzheimer's disease models comparable to donepezil [42289507]. Bismuth hybrid materials have shown exceptional dual inhibition against acetylcholinesterase (IC₅₀ = 1.96 ± 0.1 mM) and α-amylase [42171151], while a chemiluminescent acetylcholinesterase-responsive probe was developed to enable enhanced visualization of acute ischemic stroke by exploiting acetylcholinesterase upregulation under hypoxic conditions [42118815]. Additionally, organophosphate poisoning management has been advanced through development of brain-targeted metal-organic frameworks encapsulating HI-6 for central nervous system acetylcholinesterase reactivation following cholinergic system inhibition [41794176].
Molecular and structural investigations have provided mechanistic insights into acetylcholinesterase inhibition. Stereoselective inhibition studies revealed that enantiomeric norsesquiterpenoids from marine soft corals display pronounced stereoselectivity, with the (-)-enantiomer exhibiting an IC₅₀ of 10.08 µM compared to 149.8 µM for the (+)-enantiomer, demonstrating favorable drug-like properties and blood-brain barrier permeability [41740353]. Molecular docking analyses and molecular dynamics simulations have consistently supported experimental findings, elucidating optimal binding modes within the catalytic and peripheral binding regions of acetylcholinesterase and facilitating lead optimization. Computational platforms, including the CANDO multiscale drug discovery framework, have identified acetylcholinesterase as a key target among predicted glioma therapeutics, suggesting potential neuroprotective roles beyond classical Alzheimer's disease applications [41968358].